Xencor (XNCR) Leerink Global Healthcare Conference 2026 summary

Company overview and strategic priorities

• Focus on protein and antibody engineering to develop novel monoclonal and bispecific antibodies for oncology and autoimmune diseases.

• Aims to become a fully integrated company by advancing proprietary programs through clinical development to market.

• Key priorities include advancing internal clinical programs, especially XmAb819 (renal cell carcinoma) and XmAb541 (CLDN6+ tumors), and launching new autoimmune disease programs.

• Plans to deliver phase I data for XmAb819 and XmAb541 in 2024, with pivotal trials targeted for 2027.

• XmAb412, a bispecific antibody for autoimmune disease, will have its preclinical data presented at DDW in May.

Oncology pipeline: XmAb819 (ENPP3 x CD3)

• XmAb819 is a bispecific T cell engager targeting ENPP3 and CD3, designed for high efficacy and selectivity in renal cell carcinoma.

• Achieved a 25% objective response rate in heavily pretreated clear cell renal cell carcinoma patients, with durable responses and manageable safety profile.

• Dose expansion cohorts are underway to define the recommended phase III dose, with pivotal studies planned for 2027.

• Parallel development includes subcutaneous formulation and expansion into earlier-line and additional tumor types (papillary RCC, NSCLC, colorectal cancer).

• Commercial opportunity is substantial, with potential to double the market by targeting ENPP3-positive tumors beyond RCC.

Oncology pipeline: XmAb541 (CLDN6 x CD3)

• XmAb541 is a bispecific antibody for CLDN6+ tumors, showing a 30% response rate in early data across ovarian and germ cell tumors.

• Currently optimizing dose and characterizing efficacy and safety, with phase III dose decision expected by year-end.

• Future development will consider separate pathways for germ cell, endometrial, and ovarian cancers based on clinical activity and market potential.

• Competitive landscape is dense in ovarian cancer but less so in germ cell tumors; aims to differentiate through immunotherapy-like durability.